Commentary
Video
Author(s):
Samuel Cytryn, MD, and David B. Zhen, MD, on factors for selecting nivolumab plus chemotherapy or ipilimumab in esophageal squamous cell carcinoma.
177Lu-edotreotide Improves PFS in Grade 1/2 GEP-NETs in Phase 3 COMPETE Trial
Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD
Encorafenib Combination Approval Paves the Way Forward in BRAF V600E–Mutated CRC
FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer
Camrelizumab/Nab-POF Combo Increases R0 Resection Rates in Gastric/GEJ Cancer
Neoadjuvant SCRT Plus Cadonilimab/Chemo Meets pCR End Point in pMMR/MSS Rectal Cancer
OS With Chemotherapy Is Linked With Baseline Geriatric, QOL Factors in Metastatic Pancreatic Cancer
Bezuclastinib Plus Sunitinib Elicits Preliminary Activity, Is Safe in Pretreated GIST
Post-Chemotherapy ctDNA Status May Support Organ Preservation Decisions in Rectal Cancer
Adagrasib/Cetuximab Maintains Efficacy in KRAS G12C–Mutated Advanced mCRC